Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 25 Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Breast Neoplasms 13 Colonic Neoplasms 9 Uterine Cervical Neoplasms 7 Lung Neoplasms 6 Colorectal Neoplasms 6 Urinary Bladder Neoplasms 5 Melanoma 5 Leukemia, Myeloid, Acute 5 Carcinoma, Renal Cell 5 Uterine Cervical Dysplasia 4 Lymphoma, Large B-Cell, Diffuse 4 Esophageal Neoplasms 4 Brain Neoplasms 4 Thrombocythemia, Essential 3 Rectal Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Polycythemia Vera 3 Papillomavirus Infections 3 Oropharyngeal Neoplasms 3 Neuroblastoma 3 Mouth Neoplasms 3 Liver Neoplasms 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Hodgkin Disease 3 Glioma 3 Gallbladder Neoplasms 3 Carcinoma, Hepatocellular 3

Interventions

Gemcitabine 13 pembrolizumab 9 Specimen Handling 9 enfortumab vedotin 8 Cisplatin 8 Magnetic Resonance Spectroscopy 7 avelumab 5 Carboplatin 5 vinflunine 4 Nivolumab 4 atezolizumab 3 Immunoglobulin G 3 Disulfides 3 Biopsy 3 eribulin 2 cabozantinib 2 Standard of Care 2 Ramucirumab 2 Radiotherapy 2 Platinum 2 Nephroureterectomy 2 Ipilimumab 2 Doxorubicin 2 Docetaxel 2 CTLA-4 Antigen 2 Bortezomib 2 1,2-diaminocyclohexaneplatinum II citrate 2 vandetanib 1 tremelimumab 1 tocilizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Watchful Waiting × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡